Integrase Inhibitors
1 drugsAbout Integrase
Integrase is an enzyme essential for viral replication, responsible for integrating viral DNA into the host cell's genome. Inhibiting integrase prevents the virus from spreading within the body, making it a crucial drug target for certain viruses.
Integrase is a compelling target for therapeutic intervention due to its role in viral infection. Currently, there is no genetic evidence data available linking integrase to specific diseases, but its importance in viral replication makes it druggable.
Integrase is targeted by one FDA-approved drug, GENVOYA, a small molecule developed by Gilead Sciences. This drug falls into the 'Other' therapeutic area, indicating its relevance beyond common disease areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Drug Interactions with only 1 trials.
Top Integrase Drugs
Gilead Sciences is the only company with an approved drug targeting integrase.
The market is highly concentrated, suggesting high barriers to entry or a potential opportunity for new players with differentiated integrase inhibitors.
Integrase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Integrase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage and expand therapeutic options.
Integrase Clinical Trials 61 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 30 | 3 | 1 | 91% |
| Phase 2 | 5 | 2 | 1 | 2 | 67% |
| Phase 3 | 6 | 5 | 1 | 0 | 83% |
| Phase 4 | 16 | 9 | 3 | 4 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Integrase Drug Approval Timeline (2015 - 2015)
The first and only drug, GENVOYA, was approved in 2015.
The lack of recent approvals indicates potential saturation or challenges in developing new integrase inhibitors, requiring innovative approaches.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 64 clinical trials targeting Integrase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities